GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

NCT04021992 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab

Sponsor

Sun Yat-sen University